Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Quality Metrics Initiative Continues Moving Forward … Quietly

Executive Summary

Despite few public announcements and industry concerns, FDA's Office of Pharmaceutical Quality director says program is not dead.

Related Content

US FDA's Inspection Decisions To Be Swayed By Facility "History" With Foreign Regulators
FDA Lauds St. Gallen's Findings On 10 Metrics For Ensuring Drug Quality
FDA Quality Office Looks Back At 2017: Reviews Accelerated, Inspections Realigned
US FDA And OMB Should ‘Pause’ Billion-Dollar Quality Metrics Program, Industry Groups Say
FDA’s Revised Quality Metrics Program: Voluntary Now, Mandatory Later
FDA’s Quality Metrics Initiative Challenged on Enforceability
FDA Quality Metrics Proposal Sparks Objections, Disarray
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
FDA Could Release GMP Data To Prod Manufacturing Improvements





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts